Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

Video

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

The remarkable change to the guideline over the last several years, according to Jones, is the adoption of small-molecule inhibitors of B-cell receptor signaling. These include ibrutinib (Imbruvica) and idelalsib (Zydelig). Both agents are accepted as the first best alternative choice for treating relapsed disease, regardless of age, comorbidities, and other factors.

These agents appear to be safe and well-tolerated, and provide a better treatment choice in the relapsed setting compared with chemotherapy, Jones adds.

<<<

View more from the 2016 NCCN Annual Conference

Related Videos
Saad J. Kenderian, MB, CHB
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology